GB0127140D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB0127140D0
GB0127140D0 GBGB0127140.2A GB0127140A GB0127140D0 GB 0127140 D0 GB0127140 D0 GB 0127140D0 GB 0127140 A GB0127140 A GB 0127140A GB 0127140 D0 GB0127140 D0 GB 0127140D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0127140.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GBGB0127140.2A priority Critical patent/GB0127140D0/en
Publication of GB0127140D0 publication Critical patent/GB0127140D0/en
Priority to JP2003544054A priority patent/JP2005513020A/ja
Priority to PCT/EP2002/012506 priority patent/WO2003042218A1/en
Priority to US10/495,025 priority patent/US20050033052A1/en
Priority to EP02787608A priority patent/EP1442043A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
GBGB0127140.2A 2001-11-10 2001-11-10 Novel compounds Ceased GB0127140D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0127140.2A GB0127140D0 (en) 2001-11-10 2001-11-10 Novel compounds
JP2003544054A JP2005513020A (ja) 2001-11-10 2002-11-08 新規化合物
PCT/EP2002/012506 WO2003042218A1 (en) 2001-11-10 2002-11-08 Novel compounds
US10/495,025 US20050033052A1 (en) 2001-11-10 2002-11-08 Novel compounds
EP02787608A EP1442043A1 (en) 2001-11-10 2002-11-08 Condensed pyrimidone derivatives as lp-pla2 inhibitors for the treatment of atherosclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0127140.2A GB0127140D0 (en) 2001-11-10 2001-11-10 Novel compounds

Publications (1)

Publication Number Publication Date
GB0127140D0 true GB0127140D0 (en) 2002-01-02

Family

ID=9925626

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0127140.2A Ceased GB0127140D0 (en) 2001-11-10 2001-11-10 Novel compounds

Country Status (5)

Country Link
US (1) US20050033052A1 (enExample)
EP (1) EP1442043A1 (enExample)
JP (1) JP2005513020A (enExample)
GB (1) GB0127140D0 (enExample)
WO (1) WO2003042218A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014200542B2 (en) * 2007-05-11 2016-08-25 Rowan University Methods of treatment and prevention of neurodegenerative diseases and disorders
US8962633B2 (en) * 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
US9029383B2 (en) 2007-05-11 2015-05-12 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
BRPI0721697A2 (pt) 2007-05-11 2014-08-05 Univ Jefferson " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2."
EA025527B1 (ru) * 2007-05-11 2017-01-30 Томас Джефферсон Юниверсити Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
AU2011268127B2 (en) 2010-06-18 2016-01-14 Whitehead Institute For Biomedical Research PLA2G16 as a target for antiviral compounds
US8637536B2 (en) 2010-12-06 2014-01-28 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
US9273054B2 (en) 2011-07-27 2016-03-01 Glaxo Group Limited Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors
EP2739627A4 (en) 2011-07-27 2015-01-21 Glaxo Group Ltd 2,3-DIHYDROIMIDAZO- [1,2-C-] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AS LP-PLA² INHIBITORS
JP2016505053A (ja) 2013-01-25 2016-02-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｌｐ‐ＰＬＡ２の阻害剤としての二環式ピリミドン化合物
WO2014114694A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
CA2899124A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN111825695B (zh) * 2019-04-15 2022-04-12 中国科学院上海药物研究所 噁唑烷酮类化合物、其制备方法、用途及其药物组合物
CN114805389B (zh) 2019-11-09 2023-08-29 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
JP2026516205A (ja) 2023-04-18 2026-05-20 サイニューロ セラピューティクス インコーポレイテッド Ｌｐ－ｐｌａ２阻害剤と第２の薬剤の併用治療
CN118221687B (zh) 2023-07-17 2024-12-31 上海枢境生物科技有限公司 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60139429D1 (de) * 2000-02-16 2009-09-10 Smithkline Beecham Plc Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren
GB0024807D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024808D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
WO2003042218A1 (en) 2003-05-22
US20050033052A1 (en) 2005-02-10
JP2005513020A (ja) 2005-05-12
EP1442043A1 (en) 2004-08-04

Similar Documents

Publication Publication Date Title
GB0105895D0 (en) Novel compounds
AU2002359165A8 (en) Novel compounds
GB0106586D0 (en) Novel compounds
GB0126844D0 (en) Novel compounds
GB0104259D0 (en) Novel compounds
GB0102713D0 (en) Novel compounds
GB0103866D0 (en) Novel compounds
GB0102470D0 (en) Novel compounds
GB0107632D0 (en) Novel compounds
GB0102576D0 (en) Novel compounds
GB0103175D0 (en) Novel compounds
GB0107626D0 (en) Novel compounds
GB0105234D0 (en) Novel compounds
GB0107659D0 (en) Novel compounds
GB0105634D0 (en) Novel compounds
GB0100181D0 (en) Novel compounds
GB0106451D0 (en) Novel compounds
GB0100037D0 (en) Novel compounds
GB0101334D0 (en) Novel compounds
GB0100180D0 (en) Novel compounds
GB0102578D0 (en) Novel Compounds
GB0100182D0 (en) Novel compounds
GB0100187D0 (en) Novel compounds
GB0106158D0 (en) Novel Compounds
GB0106613D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)